Journal ArticleOPEN ACCESS

CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report

Clinical Case Reports (2021) 9(4) 1933-1936
DOI: 10.1002/ccr3.3909
5Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Author supplied keywords

Cite

CITATION STYLE

APA

Urbantat, R. M., Popper, V., Menschel, E., Pfeilstöcker, M., Forjan, E., Nader, A., … Koller, E. (2021). CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report. Clinical Case Reports, 9(4), 1933–1936. https://doi.org/10.1002/ccr3.3909

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free